本研究重点关注超低剂量放疗 (RT) 治疗原发性和继发性眼附属器淋巴瘤 (OAL) 的疗效和 2 年结果。对 2017 年至 2022 年间接受 4 种治疗的 OAL 患者进行回顾性分析RT 戈瑞。评估的主要和次要结果是缓解率、无进展生存期和淋巴瘤相关死亡。纳入了 21 名具有不同表现、亚型和分期的原发性和继发性 OAL 患者。眼眶肿瘤平均大小为17××16×16mm。 14例原发性OAL病例中，3例（14%）患有T1N0M0疾病，8例（38%）T2N0M0，3例（14%）T3N0M0（AJCC第8版分期）； 7 例继发性 OAL 中，4 例 (19%) 为 IE 期，2 例 (10%) 为 IIE 期，1 例 (5%) 为 IIIE 期（安娜堡分期）。超低剂量 RT 的 2 年局部和全身完全缓解率为 95%，无进展生存率为 100%。据报道，14% 的患者出现轻度干眼症，这是一种晚期治疗毒性。超低剂量 RT 成为 OAL 的一种有效且耐受性良好的治疗方法。我们的研究结果支持使用 4 Gy，显示出高完全缓解率 (95%) 和持久的疾病控制，在平均 27 个月的随访中没有明显的局部复发。我们的结果与早期的研究结果一致，验证了超低剂量放疗的治疗潜力，并强化了以最少的干预实现良好结果的概念。这种方法可能会减轻与较高辐射剂量相关的长期眼部副作用的负担，从而提高 OAL 患者的整体生活质量。版权所有 © 2024 美国眼科整形与重建外科学会，Inc.

This study focuses on the efficacy and 2-year outcomes of ultra-low-dose radiotherapy (RT) in treating primary and secondary ocular adnexal lymphoma (OAL).A retrospective analysis was conducted on patients with OAL between 2017 and 2022, treated with 4 Gy of RT. The primary and secondary outcomes assessed were response rate, progression-free survival, and lymphoma-related death.Twenty-one patients with primary and secondary OAL of diverse, presentations, subtypes, and stages were included. The orbital tumors had an average size of 17 × 16 × 16 mm. Of the 14 primary OAL cases, 3 (14%) had T1N0M0 disease, 8 (38%) T2N0M0, and 3 (14%) T3N0M0 (AJCC 8th edition staging); of the 7 secondary OALs, 4 (19%) were stage IE, 2 (10%) stage IIE, and 1 (5%) stage IIIE (Ann Arbor staging). Ultra-low-dose RT yielded a 95% complete response rate and 100% progression-free survival rates, both locally and systemically at 2 years. Mild dry eyes were reported in 14% of patients as a late treatment toxicity.Ultra-low-dose RT emerges as an effective and well-tolerated treatment approach for OAL. Our findings support the use of 4 Gy, showcasing high complete response rates (95%) and durable disease control without significant local relapses over an average follow up of 27 months. Our results align with earlier investigations, validating the curative potential of ultra-low-dose RT and reinforcing the concept of achieving favorable outcomes with minimal intervention. This approach may potentially alleviate the burden of long-term ocular side effects associated with higher radiation doses, enhancing the overall quality of life for OAL patients.Copyright © 2024 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.